Imaging Kv1.3 Expressing Memory T Cells as a Marker of Immunotherapy Response


Cancers, 14(5), 1–12.


Goggi, J. L., Khanapur, S., Ramasamy, B., Hartimath, S. V., Rong, T. J., Cheng, P., Tan, Y. X., Yeo, X. Y., Jung, S., Goay, S. S. M., Ong, S. T., Hwang, Y. Y., Chandy, K. G., & Robins, E. G.



Immune checkpoint inhibitors have shown great promise, emerging as a new pillar of treatment for cancer, however, only a relatively 33 small proportion of recipients show a durable response to treatment. Strategies that reliably differentiate durably-responding 34 tumours from non-responsive tumours are a critical unmet need. Persistent and durable immunological responses are associated 35 with the generation of memory T cells. Effector memory T cells associated with tumour response to immune therapies are 36 characterized by substantial upregulation of the potassium channel Kv1.3 after repeated antigen stimulation. We have developed a 37 new Kv1.3 targeting radiopharmaceutical, [18F]AlF-NOTA-KCNA3P, and evaluated whether it can reliably differentiate tumours 38 successfully responding to immune checkpoint inhibitor (ICI) therapy targeting PD-1 alone or combined with CLTA4. In a syngeneic 39 colon cancer model, we compared tumour retention of [ 18F]AlF-NOTA-KCNA3P with changes in the tumour immune 40 microenvironment determined by flow cytometry. Imaging with [18F]AlF-NOTA-KCNA3P reliably differentiated tumours 41 responding to ICI therapy from non-responding tumours and was associated with substantial tumour infiltration of T cells, especially 42 Kv1.3-expressing CD8+ effector memory T cells.

Go to journal

Get in Touch

We strive to provide the best for our customers, and we are always ready to help. Please let us know if you have a question for us.

Follow us